ATP6AP2 and persistent truncus arteriosus: MCC950 attenuated chamber dilation and cardiac dysfunction revealed decreased LVEDD, LVESD compared with the sh-ATP6AP2-TAC 28 days after TAC (Fig. 7A–C).